# Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

> **NCT06939127** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 38 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy
- **PROCEDURE:** Surgery
- **DRUG:** Adjuvant tislelizumab

## Key facts

- **NCT ID:** NCT06939127
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939127, "Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06939127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*